Prostacyclin Therapy for Pulmonary Arterial Hypertension Evolves Again With the Development of an Implantable Delivery System

      FOR RELATED ARTICLE, SEE PAGE 1128
      In 1976, Dr John R. Vane and his research group working at the Wellcome Physiologic Research Laboratories isolated and identified the previously postulated prostaglandin PGX as prostacyclin (PGI2), a potent arterial vasodilator with antiplatelet effects.
      • Whittaker N.
      • Bunting S.
      • Salmon J.
      • et al.
      The chemical structure of prostaglandin X (prostacyclin).
      • Moncada S.
      • Higgs E.A.
      • Vane J.R.
      Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation.
      • Bunting S.
      • Gryglewski R.
      • Moncada S.
      • Vane J.R.
      Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac arteries and inhibits platelet aggregation.
      • Hyman A.L.
      • Chapnick B.M.
      • Kadowitz P.J.
      • et al.
      Unusual pulmonary vasodilator activity of 13,14-dehydroprostacyclin methyl ester: comparison with endoperoxides and other prostanoids.
      • Kadowitz P.J.
      • Chapnick B.M.
      • Feigen L.P.
      • Hyman A.L.
      • Nelson P.K.
      • Spannhake E.W.
      Pulmonary and systemic vasodilator effects of the newly discovered prostaglandin, PGI2.
      In 1982, the Nobel Prize in Physiology or Medicine was awarded jointly to Sune K. Bergström, Bengt I. Samuelssonm, and Dr Vane “for their discoveries concerning prostaglandins and related biologically active substances.”
      • Vane J.R.
      Nobel lecture, 8th December 1982. Adventures and excursions in bioassay: the stepping stones to prostacyclin.
      To read this article in full you will need to make a payment
      Subscribe to CHEST
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Whittaker N.
        • Bunting S.
        • Salmon J.
        • et al.
        The chemical structure of prostaglandin X (prostacyclin).
        Prostaglandins. 1976; 12: 915-928
        • Moncada S.
        • Higgs E.A.
        • Vane J.R.
        Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation.
        Lancet. 1977; 1: 18-20
        • Bunting S.
        • Gryglewski R.
        • Moncada S.
        • Vane J.R.
        Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac arteries and inhibits platelet aggregation.
        Prostaglandins. 1976; 12: 897-913
        • Hyman A.L.
        • Chapnick B.M.
        • Kadowitz P.J.
        • et al.
        Unusual pulmonary vasodilator activity of 13,14-dehydroprostacyclin methyl ester: comparison with endoperoxides and other prostanoids.
        Proc Natl Acad Sci U S A. 1977; 74: 5711-5715
        • Kadowitz P.J.
        • Chapnick B.M.
        • Feigen L.P.
        • Hyman A.L.
        • Nelson P.K.
        • Spannhake E.W.
        Pulmonary and systemic vasodilator effects of the newly discovered prostaglandin, PGI2.
        J Appl Physiol Respir Environ Exerc Physiol. 1978; 45: 408-413
        • Vane J.R.
        Nobel lecture, 8th December 1982. Adventures and excursions in bioassay: the stepping stones to prostacyclin.
        Br J Pharmacol. 1983; 79: 821-838
        • Borchert J.
        • Franke J.
        • Lichey J.
        Reduction of acute pulmonary hypertension by prostacyclin.
        Cor Vasa. 1980; 22: 281-287
        • Szczeklik J.
        • Szczeklik A.
        • Nizankowski R.
        Hemodynamic effects of prostacyclin in man.
        Adv Prostaglandin Thromboxane Res. 1980; 7: 769-775
        • Guadagni D.N.
        • Ikram H.
        • Maslowski A.H.
        Haemodynamic effects of prostacyclin (PGI2) in pulmonary hypertension.
        Br Heart J. 1981 Apr; 45: 385-388
        • Barst R.J.
        • Rubin L.J.
        • Long W.A.
        • et al.
        • Primary Pulmonary Hypertension Study Group
        A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.
        N Engl J Med. 1996; 334: 296-301
        • Galiè N.
        • Humbert M.
        • Vachiery J.-L.
        • et al.
        2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).
        Eur Heart J. 2016; 37: 67-119
        • McLaughlin V.V.
        • Gaine S.P.
        • Barst R.J.
        • et al.
        • Treprostinil Study Group
        Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension.
        J Cardiovasc Pharmacol. 2003; 41: 293-299
        • Gomberg-Maitland M.
        • Tapson V.F.
        • Benza R.L.
        • et al.
        Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension.
        Am J Respir Crit Care Med. 2005; 172: 1586-1589
        • Bourge R.C.
        • Waxman A.B.
        • Gomberg-Maitland M.
        • et al.
        Treprostinil administered to treat pulmonary arterial hypertension using a fully implantable programmable intravascular delivery system: results of the DelIVery for PAH trial.
        Chest. 2016; 150: 27-34
        • Waxman A.B.
        • McElderry H.T.
        • Gomberg-Maitland M.
        • et al.
        Totally implantable IV treprostinil therapy in pulmonary hypertension: assessment of the implantation procedure.
        Chest. 2017; 152: 1128-1134